PRESS RELEASE

Q4 2025 — Press release

Q4 2025PDF · 22 pages1.9 MB
For immediate release
Johnson & Johnson reports Q4 and Full-Year 202 5 results
• 202 5 Fourth -Quarter reported sales growth of 9.1% to $ 24 .6 Billion with operational growth of 7.1%* and adjusted operational
growth of 6.1%*; 202 5 Fourth -Quarter earnings per share (EPS) of $ 2.10 and adjusted EPS of $ 2.46 , both include $(0.10) due
to the acquisition of Halda Therapeutics
• 202 5 Full-Year reported sales growth of 6.0 % to $ 94 .2 Billion with operational growth of 5.3%* and adjusted operational
growth of 4.2%*; 202 5 Full-Year earnings per share (EPS) of $ 11.03 and adjusted EPS of $ 10.79, both include $(0.10) due to the
acquisition of Halda Therapeutics
• Significant innovation including approvals of CAPLYTA for major depressive disorder and RYBREVANT FAS P RO plus
LAZCLUZE for non -small cell lung cancer, landmark data for TECVAYLI plus DARZALEX FAS P RO as a potential standard of
care as early as second line for patients with relapsed/refractory multiple myeloma, the acquisition of Halda Therapeutics ,
and submission of OTTAVA Robotic Surgical System
• Company issues guidance for 202 6 with estimated reported sale s of $100.5 Billion or 6.7% at the midpoint , and adjusted
EP S 4 of $ 11.53 or 6.9% at the midpoint
New Brunswick, N.J. ( January 2 1, 202 6) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth -quarter and
full-year 202 5. "2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history ”
said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Last year kicked off a new era of accelerated
growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuroscience ,
Cardiovascular, Surgery, and Vision. In each of these important areas, our leadersh ip is expanding driven by game -changing
science and technology .”
Overall financial results
Q4 Full Year
($ in Millions, ex cept EPS) 202 5 202 4 % Change 202 5 202 4 % Change
Reported Sales $ 24 ,564 $2 2,520 9.1% $ 94 ,193 $8 8,821 6.0 %
Net Earnings $ 5,116 $ 3,431 49 .1% $ 26,804 $ 14,06 6 90 .6 %
EPS (diluted) $ 2.10 $1.41 48 .9% $ 11.03 $5.79 90 .5%
Q4 Full Year
Non -GAAP* ($ in Millions, except EPS) 202 5 202 4 % Change 202 5 202 4 % Change
Operational Sales 1,2 7.1% 5.3%
Adjusted Operational Sales 1,3 6.1% 4.2%
Adjusted Net Earnings 1,4 $ 6,009 $ 4,946 21.5% $ 26,215 $2 4,242 8.1%
Adjusted EPS (diluted) 1,4 $ 2.46 $2.04 20 .6 % $ 10.79 $9. 98 8.1%
Free Cash Flow 5,6 ~$ 19,700 $ 19,8 42
1 Non-GAAP financial measure; refer to reconciliations of non -GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Media contact:
media-relations@its.jnj.com
Investor contact:
investor -relations@its.jnj.com

-- 1 of 22 --

4 Excludes intangible amortization expense and special items
5 Non-GAAP measure; defined as cash flow from operating activities , less additions to property, plant and equipment . Cash flow from
operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
6 Full year 202 5 is estimated as of January 21, 202 6.
Note: values may have been rounded
Regional sales results
Q4 % Change
($ in Millions) 202 5 202 4 Reported Operational 1,2 Currency
Adjusted
Operational 1,3
U.S. $ 14,195 $13,20 4 7.5% 7.5 - 5.7
International 10,369 9,316 11.3 6.6 4.7 6.8
Worldwide $ 24 ,564 $2 2,520 9.1% 7.1 2.0 6.1
Full Year % Change
($ in Millions) 202 5 202 4 Reported Operational 1,2 Currency
Adjusted
Operational 1,3
U.S. $ 53 ,752 $ 50 ,302 6.9% 6.9 - 4.9
International 40 ,441 38, 519 5.0 3.4 1.6 3.3
Worldwide $ 94 ,193 $8 8,821 6.0 % 5.3 0.7 4.2
1 Non-GAAP financial measure; refer to reconciliations of non -GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Segment sales results
Q4 % Change
($ in Millions) 202 5 202 4 Reported Operational 1,2 Currency
Adjusted
Operational 1,3
Innovative Medicine $ 15,763 $14,33 2 10.0 % 7.9 2.1 6.2
MedTech 8,801 8,188 7.5 5.8 1.7 5.9
Worldwide $ 24 ,564 $2 2,520 9.1% 7.1 2.0 6.1
Full Year % Change
($ in Millions) 202 5 202 4 Reported Operational 1,2 Currency
Adjusted
Operational 1,3
Innovative Medicine $ 60 ,401 $5 6,964 6.0 % 5.3 0.7 4.1
MedTech 33 ,792 3 1,857 6.1 5.4 0.7 4.3
Worldwide $ 94 ,193 $8 8,821 6.0 % 5.3 0.7 4.2
1 Non-GAAP financial measure; refer to reconciliations of non -GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded

-- 2 of 22 --

Full-year 202 5 segment commentary:
Operational sales* reflected below excludes the impact of translational currency .
Innovative Medicine
Innovative Medicine worldwide operational sales grew 5.3%*, with net acquisitions and divestitures positively impacting growth
by 1.2% primarily due to CAPLYTA . Growth was driven primarily by DARZALEX, CARVYKTI , ERLEADA , and
RYBREVANT /L AZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience.
Growth was partially offset by an approximate ( 1,040 ) basis points impact from STELARA in Immunology .
MedTech
MedTech worldwide operational sales grew 5.4%*, with net acquisitions and divestitures positively impacting growth by 1.1%
primarily due to Shockwave . Growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular and
wound closure products in General Surgery.
Full-year 202 6 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward -looking basis because the company is unable to
predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition -related
expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on
various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS) January 202 6
Adjusted Operational Sales 1,2
Change vs. Prior Year / Mid -point 5.4% – 6.4% / 5.9%
Operational Sales 2 / Mid-point
Change vs. Prior Year / Mid -point
$99.5B – $100.5B / $100.0B
5.7% – 6.7% / 6.2%
Estimated Reported Sales 3/ Mid-point
Change vs. Prior Year / Mid -point
$100.0B – $101.0B / $100.5B
6.2% – 7.2% / 6.7%
Adjusted Operational EPS (Diluted) 2,4 / Mid-point
Change vs. Prior Year / Mid -point
$11.28 – $11.48 / $11.38
4.5% – 6.5% / 5.5%
Adjusted EPS (Diluted) 3,4 / Mid-point
Change vs. Prior Year / Mid -point
$11.43 – $11.63 / $11.53
5.9% – 7.9% / 6.9%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: January 202 6 = $ 1.17 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast .
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the
Securities and Exchange Commission, including its Current Reports on Form 8 -K, Quarterly Reports on Form 10 -Q and Annual
Reports on Form 10 -K. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson &
Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations

-- 3 of 22 --

section of the company’s website at Investor News , as well as Innovative Medicine Newsroom , MedTech News & Events , and
www.factsabouttalc.com .
Regulatory Johnson & Johnson Submits OTTAVA Robotic Surgical System to the
U.S. Food and Drug Administration 1 Press Release
Johnson & Johnson Receives FDA Approval for TRUFILL n -BCA Liquid
Embolic System for the Treatment of Symptomatic Chronic Subdural
Hematoma
Press Release
U.S. FDA Approval of RYBREVANT FASPRO (amivantamab and
hyaluronidase -lpuj) Enables the Simplest, Shortest Administration Time
for a First -Line Combination Regimen when Combined with LAZCLUZE
(lazertinib)
Press Release
U.S. FDA approves AKEEGA as the first precision therapy for BRCA2 -
mutated metastatic castration -sensitive prostate cancer with 54%
reduction in disease progression vs standard of care
Press Release
DARZALEX FASPRO is the first and only treatment approved by the U.S.
FDA for patients with high -risk smoldering multiple myeloma Press Release
FDA approval of CAPLYTA (lumateperone ) has the potential to reset
treatment expectations, offering hope for remission in adults with
major depressive disorder
Press Release
Data Releases New clinical data highlights CAPLYTA (lumateperone ) as a promising
option for achieving remission in adults with major depressive disorder 1 Press Release
TECVAYLI monotherapy demonstrates superior progression -free and
overall survival versus standard of care as early as first relapse in
patients with multiple myeloma predominantly refractory to anti -CD38
therapy and lenalidomide 1
Press Release
RYBREVANT (amivantamab -vmjw) longer -term results show promising
and durable responses in difficult -to-treat colorectal cancer 1 Press Release
Johnson & Johnson unveils new data showing nipocalimab is the first
and only investigational FcRn blocker with potential to reduce systemic
lupus erythematosus (SLE) activity in a Phase 2 study 1
Press Release
Unprecedented results from the Phase 3 MajesTEC -3 study support
TECVAYLI plus DARZALEX FASPRO as a potential standard of care as
early as second line for patients with relapsed/refractory multiple
myeloma
Press Release
Earlier use of CARVYKTI demonstrated lasting treatment -free
remissions at 2.5 years in patients with relapsed or refractory multiple
myeloma
Press Release
Johnson & Johnson's INLEXZO (gemcitabine intravesical system)
delivers 74 percent disease -free survival at one year in BCG -
unresponsive, high -risk, papillary -only NMIBC
Press Release
New long -term data reinforces TREMFYA (guselkumab) as the only IL -23
inhibitor proven to substantially inhibit structural joint damage in active
psoriatic arthritis
Press Release
Johnson & Johnson announces first head -to-head study comparing
IMAAVY with an alternative FcRn blocker in generalized myasthenia
gravis (gMG) at AANEM Annual Meeting
Press Release
Icotrokinra maintains standout combination of therapeutic benefit and
a favorable safety profile in once -daily pill through 28 weeks in
ulcerative colitis
Press Release
TREMFYA (guselkumab ), the first and only IL -23 inhibitor with a fully
subcutaneous treatment regimen, demonstrates durable remission in
Crohn's disease at two years
Press Release

-- 4 of 22 --

Published in The Lancet: Nipocalimab significantly decreased Sjögren's
disease (SjD) activity and severity through substantial reduction in
Sjögren's -related autoantibodies
Press Release
Icotrokinra long -term results affirm promise of targeted oral peptide
with high rates of durable skin clearance and favorable safety profile in
difficult -to-treat scalp and genital psoriasis
Press Release
Subcutaneous amivantamab delivers promising 45 percent overall
response rate with median duration of 7.2 months in recurrent or
metastatic head and neck cancer
Press Release
TECVAYLI plus DARZALEX FASPRO combination regimen significantly
improves progression -free survival and overall survival versus standard
of care
Press Release
Other
Johnson & Johnson Reaches Agreement with U.S. Government to
Improve Access to Medicines and Lower Costs for Millions of
Americans; Delivers on U.S. Manufacturing and Innovation Investments 1
Press Release
Johnson & Johnson completes acquisition of Halda Therapeutics and
its novel platform to revolutionize cancer treatment and enable next -
generation oral therapi es
Press Release
Johnson & Johnson Announces Intent to Separate Its Orthopaedics
Business Press Release
1 Subsequent to the quarter
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8: 30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson &
Johnson website . A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations
section of the company's website at events -and-presentations .
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world
where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are
personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full
spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at www.jnj.com.
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding th e
net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted
ear nings per share” and “adjusted operational diluted earnings per share” excluding after -tax intangible amortization expense
and special items, are non -GAAP financial measures and should not be considered replacements for, and should be read
together with, t he most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non -
GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial
schedules of the earnings release and the Investor Relations section of the company's website at quarterly results .
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly
results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of

-- 5 of 22 --

non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including
adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and
a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at
quarterly results .
Note to investors concerning forward -looking statements:
This press release contains “forward -looking statements” as defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things: future operating and financial performance, product development, and market position and
business str ategy. The reader is cautioned not to rely on these forward -looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual r esults could vary materially from the expectations and projections of Johnson & Johnson. Risks and
uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuation s or
changes to applicable laws and regulations; competition, including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and
obtaining regulatory approvals; unc ertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring pla ns;
the impact of business combinations an d divestitures; manufacturing difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or
government action, including related to pr oduct liability claims; changes to applicable laws and regulations, including tax laws
and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and
sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of
these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10 -K,
including in the sections captioned “Cautionary Note Regarding Forward -Looking Statements” and “Item 1A. Risk Factors,” and
in Johnson & Johnson’s subsequent Quarterly Reports on Form 10 -Q and other filings with the Securities and Exchange
Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com, investor.jnj.com , or on request from
Johnson & Johnson. Any forward -looking statement made in this release speaks only as of the date of this release. Johnson &
Johnson does not undertake to update any forward -looking statement as a result of new information or future eve nts or
developments .

-- 6 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2025 2024 Total Operations Currency 2025 2024 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 9,689	$ 8,977 7.9 % 7.9 - 36,344	$ 33,970 7.0 % 7.0 -
International 6,074 5,355 13.4 7.9 5.5 24,057 22,994 4.6 2.9 1.7
15,763 14,332 10.0 7.9 2.1 60,401 56,964 6.0 5.3 0.7
MedTech
U.S. 4,506 4,227 6.6 6.6 - 17,408 16,332 6.6 6.6 -
International 4,295 3,961 8.5 4.9 3.6 16,384 15,525 5.5 4.1 1.4
8,801 8,188 7.5 5.8 1.7 33,792 31,857 6.1 5.4 0.7
U.S. 14,195 13,204 7.5 7.5 - 53,752 50,302 6.9 6.9 -
International 10,369 9,316 11.3 6.6 4.7 40,441 38,519 5.0 3.4 1.6
Worldwide 24,564	$ 22,520 9.1 % 7.1 2.0 94,193	$ 88,821 6.0 % 5.3 0.7
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FOURTH QUARTER TWELVE MONTHS
Percent Change

-- 7 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2025 2024 Total Operations Currency 2025 2024 Total Operations Currency
Sales to customers by
geographic area
U.S. 14,195	$ 13,204 7.5 % 7.5 - 53,752	$ 50,302 6.9 % 6.9 -
Europe 5,598 4,921 13.8 5.2 8.6 21,535 20,212 6.5 2.4 4.1
Western Hemisphere excluding U.S. 1,271 1,135 12.0 11.0 1.0 4,875 4,714 3.4 8.4 (5.0)
Asia-Pacific, Africa 3,500 3,260 7.4 7.2 0.2 14,031 13,593 3.2 3.1 0.1
International 10,369 9,316 11.3 6.6 4.7 40,441 38,519 5.0 3.4 1.6
Worldwide 24,564	$ 22,520 9.1 % 7.1 2.0 94,193	$ 88,821 6.0 % 5.3 0.7
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FOURTH QUARTER TWELVE MONTHS
Percent Change

-- 8 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 24,564	$ 100.0 22,520	$ 100.0 9.1
Cost of products sold 7,968 32.4 7,128 31.6 11.8
Gross Profit 16,596 67.6 15,392 68.4 7.8
Selling, marketing and administrative expenses 6,753 27.5 6,453 28.6 4.6
Research and development expense 4,252 17.3 5,298 23.5 (19.7)
In-process research and development impairments 81 0.3 17 0.1
Interest (income) expense, net (23) (0.1) (144) (0.6)
Other (income) expense, net 483 2.0 (161) (0.7)
Restructuring 84 0.4 42 0.2
Earnings before provision for taxes on income 4,966 20.2 3,887 17.3 27.8
(Benefit from)/Provision for taxes on income (150) (0.6) 456 2.1 (132.9)
Net earnings 5,116	$ 20.8 3,431	$ 15.2 49.1
Net earnings per share (Diluted) 2.10	$ 1.41	$ 48.9
Average shares outstanding (Diluted) 2,439.0 2,427.1
Effective tax rate (3.0) % 11.7 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 7,046	$ 28.7 5,421	$ 24.1 30.0
Net earnings 6,009	$ 24.5 4,946	$ 22.0 21.5
Net earnings per share (Diluted) 2.46	$ 2.04	$ 20.6
Effective tax rate 14.7 % 8.8 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FOURTH QUARTER
2025 2024

-- 9 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 94,193	$ 100.0 88,821	$ 100.0 6.0
Cost of products sold 30,256 32.1 27,471 30.9 10.1
Gross Profit 63,937 67.9 61,350 69.1 4.2
Selling, marketing and administrative expenses 23,676 25.1 22,869 25.7 3.5
Research and development expense 14,665 15.6 17,232 19.4 (14.9)
In-process research and development impairments 81 0.1 211 0.2
Interest (income) expense, net (85) (0.1) (577) (0.6)
Other (income) expense, net (7,209) (7.6) 4,694 5.3
Restructuring 228 0.2 234 0.3
Earnings before provision for taxes on income 32,581 34.6 16,687 18.8 95.2
Provision for taxes on income 5,777 6.1 2,621 3.0 120.4
Net earnings 26,804	$ 28.5 14,066	$ 15.8 90.6
Net earnings per share (Diluted) 11.03	$ 5.79	$ 90.5
Average shares outstanding (Diluted) 2,429.4 2,429.4
Effective tax rate 17.7 % 15.7 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 31,681	$ 33.6 28,979	$ 32.6 9.3
Net earnings 26,215	$ 27.8 24,242	$ 27.3 8.1
Net earnings per share (Diluted) 10.79	$ 9.98	$ 8.1
Effective tax rate 17.3 % 16.3 %
(1) See Reconciliation of Non-GAAP Financial Measures.
TWELVE MONTHS
2025 2024

-- 10 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2025 2024 2025 2024
Net Earnings, after tax- as reported $5,116 $3,431 $26,804 $14,066
Pre-tax Adjustments
Litigation related 854 (16) (6,040) 5,450
Intangible Asset Amortization expense 1,186 1,171 4,621 4,526
Restructuring related 1 210 62 512 269
Acquisition, integration and divestiture related (190) 298 285 1,226
IPR&D impairments 81 17 81 211
(Gains)/losses on securities (100) (68) (427) 306
Orthopaedics Separation related 48 - 48 -
COVID-19 Vaccine related costs - 23 - 100
Medical Device Regulation - 47 - 204
Other (9) - 20 -
Tax Adjustments
Tax impact on special item adjustments 2 (445) (80) 381 (2,135)
Tax legislation and other tax related (742) 61 (70) 19
Adjusted Net Earnings, after tax $6,009 $4,946 $26,215 $24,242
Average shares outstanding (Diluted) 2,439.0 2,427.1 2,429.4 2,429.4
Adjusted net earnings per share (Diluted) $2.46 $2.04 $10.79 $9.98
Operational adjusted net earnings per share (Diluted) $2.35 $10.58
Notes:
1
2
Fourth Quarter Twelve Months Ended
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest
benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory
syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million in fiscal 2024 included the termination of partnered and non-partnered program costs, asset
impairments and asset divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network
arrangements. The restructuring expense of $162 million in the fiscal fourth quarter of 2025 ($307 million Q4 2025 YTD) and $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) primarily
includes costs related to market and product exits. This program was substantially completed in Q4 2025.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize
select sites across the network. The restructuring expense of $48 million in the fiscal fourth quarter of 2025 ($205 million Q4 2025 YTD) primarily includes costs related to asset impairments and market and
product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

-- 11 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 10.0% 7.5% 9.1%
U.S. 7.9% 6.6% 7.5%
International 13.4% 8.5% 11.3%
WW Currency 2.1 1.7 2.0
U.S. - - -
International 5.5 3.6 4.7
WW Operational 7.9% 5.8% 7.1%
U.S. 7.9% 6.6% 7.5%
International 7.9% 4.9% 6.6%
Caplyta (1.7) (1.1)
U.S. (2.8) (1.9)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.0 0.1 0.1
U.S. 0.0 0.1 0.1
International 0.1 0.2 0.2
WW Adjusted Operational Ex A&D 6.2% 5.9% 6.1%
U.S. 5.1% 6.7% 5.7%
International 8.0% 5.1% 6.8%
Adjusted Operational Sales Growth
FOURTH QUARTER 2025 ACTUAL vs. 2024 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 6.0% 6.1% 6.0%
U.S. 7.0% 6.6% 6.9%
International 4.6% 5.5% 5.0%
WW Currency 0.7 0.7 0.7
U.S. - - -
International 1.7 1.4 1.6
WW Operational 5.3% 5.4% 5.3%
U.S. 7.0% 6.6% 6.9%
International 2.9% 4.1% 3.4%
Shockwave (1.4) (0.5)
U.S. (2.1) (0.7)
International (0.5) (0.2)
Caplyta (1.2) (0.7)
U.S. (2.1) (1.4)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.0 0.3 0.1
U.S. 0.0 0.3 0.1
International 0.1 0.2 0.1
WW Adjusted Operational Ex A&D 4.1% 4.3% 4.2%
U.S. 4.9% 4.8% 4.9%
International 3.0% 3.8% 3.3%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
TWELVE MONTHS 2025 ACTUAL vs. 2024 ACTUAL
Segments

-- 13 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
ONCOLOGY
US 3,793	$ 3,019 25.6% 25.6% - 13,659	$ 10,854 25.8% 25.8% -
Intl 3,069 2,476 23.9% 17.3% 6.6% 11,721 9,926 18.1% 15.6% 2.5%
WW 6,861 5,497 24.8% 21.9% 2.9% 25,380 20,781 22.1% 20.9% 1.2%
CARVYKTI
US 420 304 38.2% 38.2% - 1,492 869 71.6% 71.6% -
Intl 135 31 * * * 395 94 * * *
WW 555 334 65.8% 63.2% 2.6% 1,887 963 95.9% 94.3% 1.6%
DARZALEX
US 2,332 1,799 29.6% 29.6% - 8,266 6,588 25.5% 25.5% -
Intl 1,571 1,285 22.3% 16.2% 6.1% 6,085 5,082 19.7% 17.5% 2.2%
WW 3,903 3,084 26.6% 24.1% 2.5% 14,351 11,670 23.0% 22.0% 1.0%
ERLEADA
US 405 342 18.6% 18.6% - 1,453 1,282 13.4% 13.4% -
Intl 554 442 25.3% 17.5% 7.8% 2,121 1,717 23.5% 20.1% 3.4%
WW 959 784 22.4% 18.0% 4.4% 3,574 2,999 19.2% 17.2% 2.0%
IMBRUVICA
US 207 250 (17.4)% (17.4)% - 892 1,020 (12.5)% (12.5)% -
Intl 478 481 (0.8)% (7.5)% 6.7% 1,931 2,018 (4.3)% (6.7)% 2.4%
WW 684 731 (6.5)% (10.9)% 4.4% 2,823 3,038 (7.1)% (8.6)% 1.5%
RYBREVANT / LAZCLUZE (3)
US 146 101 45.6% 45.6% - 534 257 * * -
Intl 70 21 * * * 200 70 * * *
WW 216 122 78.0% 76.5% 1.5% 734 327 * * *
TALVEY
US 105 68 53.8% 53.8% - 340 241 40.9% 40.9% -
Intl 44 17 * * * 123 46 * * *
WW 149 85 75.8% 73.1% 2.7% 463 287 61.3% 60.3% 1.0%
TECVAYLI
US 110 108 2.7% 2.7% - 444 418 6.3% 6.3% -
Intl 66 38 72.2% 65.1% 7.1% 226 131 72.8% 70.4% 2.4%
WW 176 146 20.8% 18.9% 1.9% 670 549 22.1% 21.5% 0.6%
ZYTIGA / abiraterone acetate
US 5 9 (41.4)% (41.4)% - 23 34 (33.2)% (33.2)% -
Intl 115 127 (9.9)% (11.1)% 1.2% 480 597 (19.7)% (20.5)% 0.8%
WW 119 135 (11.9)% (13.0)% 1.1% 502 631 (20.4)% (21.2)% 0.8%
OTHER ONCOLOGY
US 61 39 54.8% 54.8% - 214 145 47.5% 47.5% -
Intl 39 36 8.4% 3.0% 5.4% 162 172 (6.0)% (7.8)% 1.8%
WW 100 75 32.9% 30.3% 2.6% 376 317 18.5% 17.5% 1.0%
See footnotes at end of schedule
% Change % Change

-- 14 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
IMMUNOLOGY
US 2,495	$ 2,856 (12.6)% (12.6)% - 9,872	$ 11,355 (13.1)% (13.1)% -
Intl 1,364 1,383 (1.4)% (5.5)% 4.1% 5,856 6,473 (9.5)% (10.2)% 0.7%
WW 3,860 4,238 (8.9)% (10.3)% 1.4% 15,728 17,828 (11.8)% (12.0)% 0.2%
REMICADE
US 248 231 7.1% 7.1% - 1,171 1,009 16.0% 16.0% -
US Exports (4) 11 9 17.1% 17.1% - 74 98 (24.8)% (24.8)% -
Intl 110 117 (5.6)% (7.3)% 1.7% 523 497 5.3% 6.2% (0.9)%
WW 370 359 3.2% 2.6% 0.6% 1,768 1,605 10.2% 10.5% (0.3)%
SIMPONI / SIMPONI ARIA
US 287 262 9.6% 9.6% - 1,193 1,082 10.3% 10.3% -
Intl 345 321 7.4% 3.7% 3.7% 1,475 1,108 33.1% 32.8% 0.3%
WW 632 583 8.4% 6.4% 2.0% 2,668 2,190 21.8% 21.7% 0.1%
STELARA
US 766 1,699 (54.9)% (54.9)% - 3,847 6,720 (42.7)% (42.7)% -
Intl 462 650 (28.8)% (32.3)% 3.5% 2,230 3,641 (38.7)% (39.3)% 0.6%
WW 1,230 2,349 (47.7)% (48.6)% 0.9% 6,078 10,361 (41.3)% (41.5)% 0.2%
TREMFYA
US 1,145 654 75.1% 75.1% - 3,529 2,443 44.5% 44.5% -
Intl 445 295 50.9% 44.0% 6.9% 1,626 1,227 32.5% 30.4% 2.1%
WW 1,589 949 67.6% 65.4% 2.2% 5,155 3,670 40.5% 39.8% 0.7%
OTHER IMMUNOLOGY
US 39 0 * * - 59 3 * * -
Intl 2 0 * * * 2 0 * * *
WW 40 0 * * * 61 3 * * *
NEUROSCIENCE
US 1,439 1,148 25.4% 25.4% - 5,151 4,398 17.1% 17.1% -
Intl 675 628 7.6% 4.3% 3.3% 2,686 2,718 (1.2)% (1.8)% 0.6%
WW 2,115 1,775 19.1% 17.9% 1.2% 7,837 7,115 10.1% 9.9% 0.2%
CAPLYTA (5)
US 249 - * * - 700 - * * -
Intl - - - - - - - - - -
WW 249 - * * - 700 - * * -
CONCERTA / Methylphenidate
US 6 33 (79.6)% (79.6)% - 82 134 (38.6)% (38.6)% -
Intl 126 125 (0.3)% (1.4)% 1.1% 502 507 (1.2)% (0.7)% (0.5)%
WW 132 159 (17.1)% (17.8)% 0.7% 584 641 (9.0)% (8.6)% (0.4)%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 704 796 (11.5)% (11.5)% - 2,725 3,125 (12.8)% (12.8)% -
Intl 281 267 5.2% 1.9% 3.3% 1,085 1,097 (1.1)% (1.8)% 0.7%
WW 986 1,063 (7.3)% (8.2)% 0.9% 3,810 4,222 (9.8)% (9.9)% 0.1%
SPRAVATO
US 438 269 63.0% 63.0% - 1,485 929 59.9% 59.9% -
Intl 64 28 * * * 210 148 41.9% 39.1% 2.8%
WW 503 297 69.0% 67.8% 1.2% 1,696 1,077 57.4% 57.0% 0.4%
OTHER NEUROSCIENCE
US 40 49 (18.3)% (18.3)% - 159 210 (24.5)% (24.5)% -
Intl 205 206 (0.7)% (4.3)% 3.6% 889 965 (7.9)% (8.7)% 0.8%
WW 245 255 (4.1)% (6.9)% 2.8% 1,048 1,175 (10.9)% (11.5)% 0.6%
See footnotes at end of schedule
% Change % Change

-- 15 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 865	$ 819 5.7% 5.7% - 3,223	$ 3,143 2.6% 2.6% -
Intl 319 274 16.4% 12.2% 4.2% 1,214 1,140 6.5% 4.9% 1.6%
WW 1,184 1,092 8.4% 7.4% 1.0% 4,437 4,282 3.6% 3.2% 0.4%
OPSUMIT / OPSYNVI
US 458 408 11.9% 11.9% - 1,633 1,557 4.8% 4.8% -
Intl 185 162 14.8% 10.9% 3.9% 692 668 3.7% 2.1% 1.6%
WW 643 570 12.7% 11.6% 1.1% 2,325 2,225 4.5% 4.0% 0.5%
UPTRAVI
US 397 391 1.6% 1.6% - 1,536 1,511 1.7% 1.7% -
Intl 94 75 26.9% 20.8% 6.1% 366 307 19.4% 17.4% 2.0%
WW 491 465 5.7% 4.7% 1.0% 1,902 1,817 4.7% 4.3% 0.4%
OTHER PULMONARY HYPERTENSION
US 10 19 (43.7)% (43.7)% - 54 75 (27.0)% (27.0)% -
Intl 39 38 2.6% 1.2% 1.4% 155 165 (6.2)% (6.8)% 0.6%
WW 49 57 (12.5)% (13.5)% 1.0% 209 240 (12.7)% (13.0)% 0.3%
INFECTIOUS DISEASES
US 303 331 (8.5)% (8.5)% - 1,264 1,354 (6.6)% (6.6)% -
Intl 505 443 13.9% 5.6% 8.3% 1,977 2,042 (3.2)% (6.5)% 3.3%
WW 807 774 4.3% (0.4)% 4.7% 3,241 3,396 (4.6)% (6.5)% 1.9%
EDURANT / rilpivirine
US 5 7 (39.1)% (39.1)% - 26 31 (18.4)% (18.4)% -
Intl 379 315 20.6% 11.1% 9.5% 1,461 1,241 17.7% 13.0% 4.7%
WW 383 322 19.2% 9.9% 9.3% 1,486 1,272 16.9% 12.2% 4.7%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 294 321 (8.4)% (8.4)% - 1,226 1,311 (6.5)% (6.5)% -
Intl 89 86 3.6% (2.9)% 6.5% 353 401 (11.9)% (13.7)% 1.8%
WW 383 407 (5.8)% (7.2)% 1.4% 1,579 1,712 (7.7)% (8.1)% 0.4%
OTHER INFECTIOUS DISEASES
US 4 1 92.9% 92.9% - 12 11 6.6% 6.6% -
Intl 37 43 (14.5)% (18.0)% 3.5% 163 401 (59.3)% (59.5)% 0.2%
WW 40 45 (9.9)% (13.2)% 3.3% 175 412 (57.5)% (57.7)% 0.2%
CARDIOVASCULAR / METABOLISM / OTHER
US 794 805 (1.4)% (1.4)% - 3,175 2,866 10.8% 10.8% -
Intl 142 153 (6.3)% (10.7)% 4.4% 603 696 (13.3)% (13.8)% 0.5%
WW 936 957 (2.2)% (2.9)% 0.7% 3,778 3,562 6.1% 6.0% 0.1%
XARELTO
US 687 676 1.7% 1.7% - 2,633 2,373 11.0% 11.0% -
Intl - - - - - - - - - -
WW 687 676 1.7% 1.7% - 2,633 2,373 11.0% 11.0% -
OTHER
US 107 130 (17.4)% (17.4)% - 542 494 9.8% 9.8% -
Intl 142 153 (6.3)% (10.7)% 4.4% 603 696 (13.3)% (13.8)% 0.5%
WW 249 281 (11.4)% (13.8)% 2.4% 1,145 1,189 (3.7)% (4.0)% 0.3%
TOTAL INNOVATIVE MEDICINE
US 9,689 8,977 7.9% 7.9% - 36,344 33,970 7.0% 7.0% -
Intl 6,074 5,355 13.4% 7.9% 5.5% 24,057 22,994 4.6% 2.9% 1.7%
WW 15,763	$ 14,332 10.0% 7.9% 2.1% 60,401	$ 56,964 6.0% 5.3% 0.7%
See footnotes at end of schedule
% Change % Change

-- 16 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
MEDTECH SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,374	$ 1,221 12.5% 12.5% - 5,305	$ 4,513 17.5% 17.5% -
Intl 925 841 10.1% 6.8% 3.3% 3,623 3,194 13.4% 11.9% 1.5%
WW 2,299 2,062 11.5% 10.1% 1.4% 8,928 7,707 15.8% 15.2% 0.6%
ELECTROPHYSIOLOGY
US 746 681 9.5% 9.5% - 2,891 2,738 5.6% 5.6% -
Intl 679 640 6.2% 3.2% 3.0% 2,743 2,529 8.5% 7.3% 1.2%
WW 1,425 1,321 7.9% 6.5% 1.4% 5,634 5,267 7.0% 6.4% 0.6%
ABIOMED
US 358 308 16.5% 16.5% - 1,393 1,213 14.9% 14.9% -
Intl 102 77 33.1% 25.4% 7.7% 358 284 26.4% 22.0% 4.4%
WW 460 384 19.8% 18.3% 1.5% 1,751 1,496 17.1% 16.2% 0.9%
SHOCKWAVE
US 238 202 18.0% 18.0% - 897 442 * * -
Intl 80 56 42.3% 40.7% 1.6% 249 122 * * *
WW 318 258 23.3% 22.9% 0.4% 1,146 564 * * *
OTHER CARDIOVASCULAR
US 31 31 (0.1)% (0.1)% - 124 120 3.1% 3.1% -
Intl 64 68 (6.7)% (8.8)% 2.1% 273 260 4.9% 4.1% 0.8%
WW 95 99 (4.6)% (6.1)% 1.5% 397 380 4.3% 3.8% 0.5%
ORTHOPAEDICS
US 1,520 1,460 4.2% 4.2% - 5,720 5,689 0.5% 0.5% -
Intl 918 856 7.3% 2.3% 5.0% 3,538 3,470 2.0% (0.2)% 2.2%
WW 2,438 2,315 5.3% 3.5% 1.8% 9,258 9,158 1.1% 0.3% 0.8%
HIPS
US 284 272 4.3% 4.3% - 1,080 1,057 2.1% 2.1% -
Intl 154 146 5.5% 0.4% 5.1% 594 581 2.2% 0.1% 2.1%
WW 439 418 4.7% 2.9% 1.8% 1,674 1,638 2.1% 1.4% 0.7%
KNEES
US 251 238 5.1% 5.1% - 924 922 0.2% 0.2% -
Intl 181 160 13.7% 9.2% 4.5% 663 623 6.5% 4.6% 1.9%
WW 432 398 8.6% 6.8% 1.8% 1,587 1,545 2.7% 2.0% 0.7%
TRAUMA
US 543 514 5.6% 5.6% - 2,058 2,013 2.2% 2.2% -
Intl 270 250 7.9% 2.7% 5.2% 1,088 1,036 5.0% 2.7% 2.3%
WW 813 764 6.4% 4.7% 1.7% 3,146 3,049 3.2% 2.4% 0.8%
SPINE, SPORTS & OTHER
US 442 434 1.9% 1.9% - 1,658 1,696 (2.2)% (2.2)% -
Intl 312 300 4.2% (0.7)% 4.9% 1,193 1,230 (3.0)% (5.3)% 2.3%
WW 756 735 2.8% 0.8% 2.0% 2,852 2,926 (2.5)% (3.5)% 1.0%
See footnotes at end of schedule
% Change % Change

-- 17 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
SURGERY
US 1,081	$ 1,038 4.2% 4.2% - 4,157	$ 4,003 3.9% 3.9% -
Intl 1,563 1,469 6.4% 3.4% 3.0% 5,980 5,842 2.4% 1.5% 0.9%
WW 2,644 2,507 5.5% 3.7% 1.8% 10,137 9,845 3.0% 2.5% 0.5%
ADVANCED
US 489 478 2.5% 2.5% - 1,900 1,838 3.4% 3.4% -
Intl 687 673 1.9% (0.8)% 2.7% 2,678 2,650 1.0% 0.1% 0.9%
WW 1,175 1,151 2.2% 0.6% 1.6% 4,577 4,488 2.0% 1.5% 0.5%
GENERAL
US 592 560 5.6% 5.6% - 2,258 2,165 4.3% 4.3% -
Intl 876 795 10.2% 6.9% 3.3% 3,302 3,192 3.4% 2.7% 0.7%
WW 1,468 1,357 8.3% 6.3% 2.0% 5,560 5,358 3.8% 3.3% 0.5%
VISION
US 531 509 4.3% 4.3% - 2,225 2,128 4.6% 4.6% -
Intl 889 794 11.9% 8.5% 3.4% 3,243 3,018 7.4% 5.9% 1.5%
WW 1,420 1,303 8.9% 6.8% 2.1% 5,468 5,146 6.3% 5.3% 1.0%
CONTACT LENSES / OTHER
US 417 396 5.3% 5.3% - 1,754 1,684 4.1% 4.1% -
Intl 592 541 9.3% 5.3% 4.0% 2,157 2,049 5.3% 3.2% 2.1%
WW 1,008 937 7.6% 5.3% 2.3% 3,910 3,733 4.8% 3.6% 1.2%
SURGICAL
US 113 113 0.6% 0.6% - 471 444 6.1% 6.1% -
Intl 297 252 17.7% 15.3% 2.4% 1,086 969 12.1% 11.6% 0.5%
WW 411 365 12.4% 10.8% 1.6% 1,558 1,413 10.2% 9.9% 0.3%
TOTAL MEDTECH
US 4,506 4,227 6.6% 6.6% - 17,408 16,332 6.6% 6.6% -
Intl 4,295 3,961 8.5% 4.9% 3.6% 16,384 15,525 5.5% 4.1% 1.4%
WW 8,801	$ 8,188 7.5% 5.8% 1.7% 33,792	$ 31,857 6.1% 5.4% 0.7%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore,
may not recalculate precisely
% Change % Change

-- 18 of 22 --

Innovative Medicine
Fourth Quarter
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Fourth Quarter
Dec. 28, 2025
Non-GAAP
Cost of products sold 3,976	$ (704) (11) 3,261
Selling, marketing and admin expenses 3,456 3,456
Research and development expense 3,466 3,466
Other segment items (193) 16 (11) (52) 101 4 (135)
Adjusted Income Before Tax by Segment 5,058 704 (16) 11 - 63 (101) - - (4) 5,715
MedTech
Fourth Quarter
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Fourth Quarter
Dec. 28, 2025
Non-GAAP
Cost of products sold 3,973	$ (482) (56) 3,435
Selling, marketing and admin expenses 3,035 3,035
Research and development expense 786 786
Other segment items 806 (818) (70) (154) 290 (1) (48) 5 10
Adjusted Income Before Tax by Segment 201 482 818 70 210 (290) 1 48 - (5) 1,535
Expenses not allocated to segments
Fourth Quarter
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Fourth Quarter
Dec. 28, 2025
Non-GAAP
Cost of products sold 19	$ 19
Selling, marketing and admin expenses 262 262
Research and development expense - -
Other segment items 12 (52) (37) (77)
Adjusted Income Before Tax by Segment (293) - 52 - - 37 - - - - (204)
Johnson & Johnson Consolidated
Fourth Quarter
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Fourth Quarter
Dec. 28, 2025
Non-GAAP
Cost of products sold 7,968	$ (1,186) (56) (11) 6,715
Selling, marketing and admin expenses 6,753 6,753
Research and development expense 4,252 4,252
Other (Income) / Expense 483 (854) (70) 201 100 (48) 9 (179)
In-process research and development impairments 81 (81) -
Interest (Income)/Expense (23) (23)
Restructuring 84 (84) -
Adjusted Income Before Tax 4,966 1,186 854 81 210 (190) (100) 48 - (9) 7,046
Provision for taxes on income (150) 226 32 18 35 149 (23) 11 742 (3) 1,037
Net Earnings 5,116	$ 960 822 63 175 (339) (77) 37 (742) (6) 6,009
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 19 of 22 --

Innovative Medicine
Fourth Quarter
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Fourth Quarter
Dec. 29, 2024
Non-GAAP
Cost of products sold 3,514	$ (685) 2,829
Selling, marketing and admin expenses 3,312 3,312
Research and development expense 3,698 (6) 3,692
Other segment items (201) 41 (17) (2) (12) 50 (17) (158)
Adjusted Income Before Tax by Segment 4,009 685 (41) 17 2 12 (50) - 23 - 4,657
MedTech
Fourth Quarter
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Fourth Quarter
Dec. 29, 2024
Non-GAAP
Cost of products sold 3,596	$ (477) (20) (153) (18) 2,928
Selling, marketing and admin expenses 2,836 (4) 2,832
Research and development expense 1,600 (25) 1,575
Other segment items 84 (9) 29 (40) (115) 18 (33)
Adjusted Income Before Tax by Segment 72 486 (29) - 60 268 (18) 47 - - 886
Expenses not allocated to segments
Fourth Quarter
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Fourth Quarter
Dec. 29, 2024
Non-GAAP
Cost of products sold 18	$ 18
Selling, marketing and admin expenses 305 305
Research and development expense - -
Other segment items (129) (54) (18) (201)
Adjusted Income Before Tax by Segment (194) - 54 - - 18 - - - - (122)
Johnson & Johnson Consolidated
Fourth Quarter
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Fourth Quarter
Dec. 29, 2024
Non-GAAP
Cost of products sold 7,128	$ (1,162) (20) (153) (18) 5,775
Selling, marketing and admin expenses 6,453 (4) 6,449
Research and development expense 5,298 (25) (6) 5,267
Other (Income) / Expense (161) (9) 16 (145) 68 (17) (248)
In-process research and development impairments 17 (17) -
Interest (Income)/Expense (144) (144)
Restructuring 42 (42) -
Adjusted Income Before Tax 3,887 1,171 (16) 17 62 298 (68) 47 23 - 5,421
Provision for taxes on income 456 171 (158) 4 3 80 (34) 9 5 (61) 475
Net Earnings 3,431	$ 1,000 142 13 59 218 (34) 38 18 61 4,946
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 20 of 22 --

Year to Date
Innovative Medicine
Twelve Months
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Twelve Months
Dec. 28, 2025
Non-GAAP
Cost of products sold 15,646	$ (2,706) (35) 12,905
Selling, marketing and admin expenses 11,375 11,375
Research and development expense 11,827 11,827
Other segment items (713) 90 (11) (327) 265 (10) (706)
Adjusted Income Before Tax by Segment 22,266 2,706 (90) 11 - 362 (265) - - 10 25,000
MedTech
Twelve Months
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Twelve Months
Dec. 28, 2025
Non-GAAP
Cost of products sold 14,549	$ (1,915) (91) (52) 12,491
Selling, marketing and admin expenses 11,354 11,354
Research and development expense 2,838 37 2,875
Other segment items 938 (896) (70) (421) 135 162 (48) (10) (210)
Adjusted Income Before Tax by Segment 4,113 1,915 896 70 512 (120) (162) 48 - 10 7,282
Expenses not allocated to segments
Twelve Months
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Twelve Months
Dec. 28, 2025
Non-GAAP
Cost of products sold 61	$ 61
Selling, marketing and admin expenses 947 947
Research and development expense - -
Other segment items (7,210) 6,846 (43) (407)
Adjusted Income Before Tax by Segment 6,202 - (6,846) - - 43 - - - - (601)
Johnson & Johnson Consolidated
Twelve Months
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Twelve Months
Dec. 28, 2025
Non-GAAP
Cost of products sold 30,256	$ (4,621) (91) (87) 25,457
Selling, marketing and admin expenses 23,676 23,676
Research and development expense 14,665 37 14,702
Other (Income) / Expense (7,209) 6,040 (193) (235) 427 (48) (20) (1,238)
In-process research and development impairments 81 (81) -
Interest (Income)/Expense (85) (85)
Restructuring 228 (228) -
Adjusted Income Before Tax 32,581 4,621 (6,040) 81 512 285 (427) 48 - 20 31,681
Provision for taxes on income 5,777 829 (1,509) 18 93 267 (96) 11 70 6 5,466
Net Earnings 26,804	$ 3,792 (4,531) 63 419 18 (331) 37 (70) 14 26,215
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 21 of 22 --

Innovative Medicine
Twelve Months
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Twelve Months
Dec. 29, 2024
Non-GAAP
Cost of products sold 14,036	$ (2,772) (8) 11,256
Selling, marketing and admin expenses 10,906 10,906
Research and development expense 13,529 (25) 13,504
Other segment items (426) (358) (211) (102) (66) 76 (67) (1,154)
Adjusted Income Before Tax by Segment 18,919 2,772 358 211 102 66 (76) - 100 - 22,452
MedTech
Twelve Months
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Twelve Months
Dec. 29, 2024
Non-GAAP
Cost of products sold 13,345	$ (1,745) (35) (359) (84) 11,122
Selling, marketing and admin expenses 10,812 (16) 10,796
Research and development expense 3,703 (69) (104) 3,530
Other segment items 257 (9) 14 (132) (587) (30) (487)
Adjusted Income Before Tax by Segment 3,740 1,754 (14) - 167 1,015 30 204 - - 6,896
Expenses not allocated to segments
Twelve Months
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Twelve Months
Dec. 29, 2024
Non-GAAP
Cost of products sold 90	$ 90
Selling, marketing and admin expenses 1,151 1,151
Research and development expense - -
Other segment items 4,731 (5,106) (145) (352) (872)
Adjusted Income Before Tax by Segment (5,972) - 5,106 - - 145 352 - - - (369)
Johnson & Johnson Consolidated
Twelve Months
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Twelve Months
Dec. 29, 2024
Non-GAAP
Cost of products sold 27,471	$ (4,517) (35) (359) (84) (8) 22,468
Selling, marketing and admin expenses 22,869 (16) 22,853
Research and development expense 17,232 (69) (104) (25) 17,034
Other (Income) / Expense 4,694 (9) (5,450) (798) (306) (67) (1,936)
In-process research and development impairments 211 (211) -
Interest (Income)/Expense (577) (577)
Restructuring 234 (234) -
Adjusted Income Before Tax 16,687 4,526 5,450 211 269 1,226 306 204 100 - 28,979
Provision for taxes on income 2,621 644 1,066 47 45 302 (29) 38 22 (19) 4,737
Net Earnings 14,066	$ 3,882 4,384 164 224 924 335 166 78 19 24,242
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Year to Date

-- 22 of 22 --